Astellas Gene Therapies Deal History & Licensing Activity
Astellas Gene Therapies is a biotech headquartered in Switzerland. Over the past three years, Astellas Gene Therapies has been involved in 2 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (1 deal). The company currently has 6 active clinical trials, primarily in Oncology.
Deals (12mo)
3
Active Trials
6
Top Modality
Bispecific Antibodies
Focus Area
Oncology
Astellas Gene Therapies Pipeline Focus
Therapeutic areas and modalities where Astellas Gene Therapies is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Astellas Gene Therapies Strategic Signals
Key indicators of Astellas Gene Therapies's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Astellas Gene Therapies Clinical Pipeline
Astellas Gene Therapies has 6 active clinical trials across 4 development phases.
2
Unknown
1
Not Applicable
2
Phase 1
1
Phase 2
See How Your Asset Matches Astellas Gene Therapies's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Astellas Gene Therapies Licensing & Deal Activity
Astellas Gene Therapies is a biotech company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Astellas Gene Therapies ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Astellas Gene Therapies include Oncology (2 deals and trials), and Rare Disease (2 deals and trials). In terms of modality, Astellas Gene Therapies has shown particular interest in bispecific antibodies, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Astellas Gene Therapies and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Astellas Gene Therapies's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.